Company

Wanbangde Receives FDA Feedback Endorsing Pivotal Phase III Path for WP205 Mecobalamin Injection in ALS
Clinical trial filingsRare / orphan disease drugs

Wanbangde Receives FDA Feedback Endorsing Pivotal Phase III Path for WP205 Mecobalamin Injection in ALS

Wanbangde Pharmaceutical Holding Group Co., Ltd. (WEPON) (SHE: 002082) announced that it has received written feedback from the U.S. Food and Drug Administration (FDA) regarding its plan to conduct a…

BMS Q3 Revenue Rises 7% to USD 13.1 Billion as Eliquis Surges 25% and Growth Portfolio Climbs 12%; Full‑Year Outlook Raised

BMS Q3 Revenue Rises 7% to USD 13.1 Billion as Eliquis Surges 25% and Growth Portfolio Climbs 12%; Full‑Year Outlook Raised

Sino Biopharmaceutical's CTTQ Partners with Revvity to Launch X‑Lab Joint Shared Laboratory for Antibody Drug R&D

Sino Biopharmaceutical’s CTTQ Partners with Revvity to Launch X‑Lab Joint Shared Laboratory for Antibody Drug R&D

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
CancerEPA: IPN

Ipsen to Acquire Kartos Therapeutics for $450M Upfront, Adding Investigational MDM2 Inhibitor Navtemadlin to Myelofibrosis Pipeline

Cereblink TechnologyInnovative Medical Management

Innovative Medical Management Subsidiary Cereblink Secures Registration for AM5 Upper Limb Rehabilitation Exoskeleton – EMG-Driven System Targets CNS Injury Recovery

Hua Medicine Completes Greater China Rollout as Dorzagliatin Gains Macau Approval – First-in-Class Glucokinase Activator Now Available Across All Chinese Territories
DiabetesHKG: 2552

Hua Medicine Completes Greater China Rollout as Dorzagliatin Gains Macau Approval – First-in-Class Glucokinase Activator Now Available Across All Chinese Territories

AbbVie's SKYRIZI Wins FDA Approval for Pediatric Psoriasis, Expanding IL-23 Blocker to Children Six and Older
AbbVieAuto-immune

AbbVie’s SKYRIZI Wins FDA Approval for Pediatric Psoriasis, Expanding IL-23 Blocker to Children Six and Older

Show More